Filing Details

Accession Number:
0001209191-23-014280
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-01 18:21:08
Reporting Period:
2023-02-27
Accepted Time:
2023-03-01 18:21:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1446847 Ironwood Pharmaceuticals Inc IRWD Pharmaceutical Preparations (2834) 043404176
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1808509 Michael Shetzline C/O Ironwood Pharmaceuticals, Inc.
100 Summer Street, Suite 2300
Boston MA 02110
Cmo,Svp,Head-Res&Drug No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Disposition 2023-02-27 7,146 $11.41 273,762 No 4 S Direct
Class A Common Stock Disposition 2023-02-27 2,322 $11.41 271,440 No 4 S Direct
Class A Common Stock Disposition 2023-02-28 7,438 $11.31 264,002 No 4 S Direct
Class A Common Stock Disposition 2023-02-28 2,416 $11.31 261,586 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020 and April 24, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
  4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.